Global: Laboratory monitoring of ART could be cost-effective for many countries

Laboratory monitoring to determine when to switch to second-line treatment may be cost-effective for many countries and could substantially improve life expectancy, April Kimmel and colleagues reported in a modelling study using 1999 to 2008 data from the Ivory Coast (Côte d’Ivoire) published in the advance online edition of the Journal of Acquired Immune Deficiency Syndromes.